linjc16/ctgov huggingface dataset:
The Pharmacological Basis for the Increase in Visual Time Constants Induced by Single Oral Doses of Sildenafil

Study Overview
=================
Brief Summary
-----------------
Sildenafil and similar drugs have been used for several years to treat erectile dysfunction. It has been noticed that in some people, sildenafil causes a subtle increase in the length of time that visual images that we see are retained by the retina. It is thought that this might be due to an effect of sildenafil on inhibiting an enzyme called phosphodiesterase type 6 (PDE6) which is present in the retina. By giving single oral doses of sildenafil and a similar drug called tadalafil which has less effect on PDE6, we hypothesise that this is the mechanism of the change in vision caused by sildenafil. By performing computerised visual test, we plan to compare the effects of sildenafil, tadalafil and placebo tablets on vision in healthy volunteers.

Official Title
-----------------
The Pharmacological Basis for the Increase in Visual Time Constants Induced by Single Oral Doses of Sildenafil

Conditions
-----------------
Erectile Dysfunction

Intervention / Treatment
-----------------
* Drug: sildenafil
* Drug: tadalafil
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy Male 18-55 years Exclusion Criteria: Significant medical or psychiatric illness Cardiac disease Hyper or hypotension Renal disease Liver disease Stroke Sickle cell anaemia Multiple myeloma Leukaemia Bleeding disorders Peyronie's disease Priapism Subjects receiving prescribed medications Subjects with known visual abnormalities other than refractive errors, including retinitis pigmentosa, optic neuropathy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: sildenafil|nan|
|Drug: tadalafil|nan|
|Drug: placebo|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| visual persistence |  |  | 
| reaction time |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sildenafil, tadalafil, phosphodiesterase, visual persistence, reaction time
microRNAs Role in Pre-eclampsia Diagnosis

Study Overview
=================
Brief Summary
-----------------
Pre-eclampsia is one of the most threatening pregnancy complications. So far neither a secure, competent therapy for PE nor effective biomarkers for a premature discovery has been achieved.The aim of our study was to identify miRNAs 136, 494 and 495 genes expression in exosomes of peripheral blood compared to umbilical cord mesenchymal stem cells conditioned media released exososomes in patients with PE, as valuable markers for PE early prediction.

Official Title
-----------------
Role of Mesenchymal Stem Cells Exosomes Derived microRNAs; miR-136, miR-494 and miR-495 in Pre-eclampsia Diagnosis and Evaluation

Conditions
-----------------
Preeclampsia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: To have an uncomplicated pregnancy: gestational age at venipuncture between 20 - 42 weeks no medical, obstetrical, or surgical complications absence of labor at the time of venipuncture delivery of a normal term (≥ 37 weeks) neonate whose birth weight was between the 10th and 90th percentile for gestational age Exclusion Criteria: Patients with chronic hypertension, renal disease, and fetuses affected with congenital anomalies were excluded

Ages Eligible for Study
-----------------
Minimum Age: 23 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control group<br>Blood samples were collected from 100 control with normal pregnancies. Thirty fresh umbilical cord samples of women with healthy pregnancies (n=15) were retrieved during caesarean deliveries and umibilical cord mesenchymal stem cells (UCMSCs) were isolated from Wharton jelly. | |
| Preeclampsia group<br>Blood samples were collected from 100 patients with PE. Thirty fresh umbilical cord samples of PE patients (n=15) were retrieved during caesarean deliveries and UCMSCs were isolated from Wharton jelly. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The expression of miRNAs 136, 494 and 495 in exosomes of peripheral blood and UCMSCs conditioned media |  | 2-3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
microRNAs, mesenchymal stem cells, exosomes, preeclampsia
Effect of the PIPAC on the Survival Rate of Patients With Peritoneal Carcinomatosis of Gastric Origin

Study Overview
=================
Brief Summary
-----------------
Pressurised intraperitoneal aerosol chemotherapy is a new surgical technique, developed for the treatment of initially unresectable peritoneal carcinomatosis. The objective of this study was to compare the results of PIPAC associated with systemic chemotherapy with those of systemic chemotherapy alone in patients with gastric peritoneal carcinomatosis without metastasis other than peritoneal, and WHO performance status <3.

Official Title
-----------------
Effect of Pressurised Intraperitoneal Aerosol Chemotherapy on the Survival Rate of Patients With Peritoneal Carcinomatosis of Gastric Origin

Conditions
-----------------
Carcinomatosis, Peritoneal

Intervention / Treatment
-----------------
* Drug: PIPAC with systemic chemotherapy
* Drug: Systemic chemotherapy alone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients 18 years or over Patients with adenocarcinoma-type gastric non-resectable péritonéale carcinomatosis. Patients without metastasis other than peritoneal. WHO performance status <3 Patients treated either with PIPAC administered in alternation with systemic chemotherapy (PIPAC_CHEM) or by systemic chemotherapy alone (ONLY_CHEM) Patient informed Exclusion Criteria: - Patients opposed

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PIPAC CHEM<br>PIPAC associated with systemic chemotherapy | Drug: PIPAC with systemic chemotherapy<br>* PIPAC procedures were performed every 6 to 8 weeks, alternating with systemic chemotherapy, replacing a cycle of intravenous chemotherapy.<br>|
| ONLY CHEM<br>systemic chemotherapy alone | Drug: Systemic chemotherapy alone<br>* Intravenous chemotherapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival at 6 months | Overall survival at 6 months from diagnosis of carcinomatosis | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of hospital stay | duration of hospitalization up to 6 months after the diagnosis of carcinomatosis | 6 months | 
| overall survival from the diagnosis of carcinomatosis and from the diagnosis of the primary tumour. | overall survival throughout the study follow-up from the diagnosis of carcinomatosis and from the diagnosis of the primary tumour. | 3 years |
Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate a complete acne regimen consisting of a medication (Benzaknen® 5% Gel), and 2 cosmetic products Dermotivin® Soft Liquid soap and Cetaphil® Dermacontrol Moisturizer SPF30 in patients with acne.

Detailed Description
-----------------
The main objective of this study is to evaluate subject satisfaction with the treatment regimen comprising Benzaknen® 5% Gel in association with 2 cosmetic products including a foam soap, Dermotivin® Soft Liquid soap, and a non comedogenic moisturizer, Cetaphil® Dermacontrol Moisturizer SPF30, in patients with mild to moderate acne, after 12 weeks of treatment.

Official Title
-----------------
Benzaknen® 5% Gel in Combination With Dermotivin® Soft Liquid Soap and Non-comedogenic Cetaphil® Dermacontrol Moisturizer SPF30 in the Treatment of Mild-to-moderate Acne Vulgaris

Conditions
-----------------
Acne Vulgaris

Intervention / Treatment
-----------------
* Drug: Benzoyl Peroxide
* Other: Dermotivin® Soft Liquid cleanser
* Other: Cetaphil® Dermacontrol Moisturizer SPF30


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female subject of any ethnic background of 12 years or older. Subject with mild or moderate facial acne vulgaris defined as an Investigator Global Assessment (IGA) score at 2 or 3 on a 0-4 scale. Subject with any skin phototype according to T.B. Fitzpatrick skin phototype definitions. Exclusion Criteria: Subject with severe acne (IGA>3) with nodules, cysts, scars or extra-facial lesions, Female subject who is pregnant, lactating or planning a pregnancy during the study, Subject susceptible to take a corticosteroid treatment during the study except inhaled or topic when needed to treat a condition outside the face,

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Benzaknen treatment regimen<br>Benzac® 5% Gel (once daily) + Dermotivin® Soft Liquid soap (twice daily) + Cetaphil® Dermacontrol Moisturizer SPF30 (once daily) | Drug: Benzoyl Peroxide<br> <br> Other: Dermotivin® Soft Liquid cleanser<br> <br> Other: Cetaphil® Dermacontrol Moisturizer SPF30<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants Satisfied and Very Satisfied With Regimen | Number of subjects satisfied and very satisfied with the three-part treatment regimen | 12 weeks |
Messaging Therapy for Depression and Anxiety: A Longitudinal Effectiveness Study

Study Overview
=================
Brief Summary
-----------------
Therapies delivered via technology have been developed to improve accessibility, however, there is limited research regarding messaging therapy in particular, and none that we know of utilizing a longitudinal effectiveness design. The aim of this study was to investigate the overall effectiveness of messaging therapy, identify any contributors to its effectiveness, and to evaluate a dosage effect for this type of treatment.

Official Title
-----------------
Asynchronous Messaging Therapy for Depression and Anxiety: A Longitudinal Study

Conditions
-----------------
Depressive Symptoms, Anxiety Disorders

Intervention / Treatment
-----------------
* Behavioral: psychotherapy via asynchronous message


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed Depression and/or Anxiety Disorder Exclusion Criteria: Any psychosis related symptoms or disorders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: psychotherapy via asynchronous message|Behavioral psychotherapy delivered by asynchronous message using the Talkspace application|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline in Depressive symptoms on the Patient Health Questionnaire - 9 | Patient Health Questionnaire - 9 (PHQ-9) is a measure of depression symptoms. It has 9 items, with a minimum of 0 and a maximum of 27, with higher scores indicating more symptoms and distress. Decreasing scores indicate better outcome. All items are summed to give the summary score. | Up to 52 weeks | 
| Change from Baseline in Anxiety symptoms on the Generalized Anxiety Disorder - 7 | Generalized Anxiety Disorder - 7 (GAD-7) is a measure of anxiety symptoms. It has 7 items, with a minimum of 0 and a maximum of 21, with higher scores indicating more symptoms and distress. Decreasing scores indicate better outcome. All items are summed to give the summary score. | Up to 52 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean number of words sent from patient to therapist | Word counts of the words contained within messages sent | Up to 52 weeks | 
| Mean number of words sent from therapist to patient | Word counts of the words contained within messages sent | Up to 52 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
anxiety, telehealth, technology, messaging psychotherapy, depression
Comparison of Interscalene and Pericapsular Nerve Group (PENG) Block in Shoulder Surgery

Study Overview
=================
Brief Summary
-----------------
Early postoperative pain after shoulder surgery is a major concern and distress for patients and orthopedic surgeons. Adequate pain control; It is vital for all aspects of patient recovery, including mental state, nutrition, cost of care period, rehabilitation, patient satisfaction, and overall post-surgery outcomes.Single analgesic regimens are not always effective in controlling moderate to severe postoperative pain.Therefore, multimodal pain management is preferred and is currently recommended for early postoperative pain control.Regional anesthesia is preferred in shoulder surgery as an effective way to provide anesthesia and postoperative analgesia.To ensure adequate postoperative pain control, nerve supply to the synovium, capsule, joint surfaces, ligaments, periosteum and shoulder muscles must be blocked.Interscalene blocks are well studied and established means of providing analgesia following shoulder surgery and are considered the gold standard mode of regional anesthesia.Pericapsular nerve group block is a new block that provides a pericapsular distribution with local anesthetic infiltration around the glenohumeral joint and provides analgesia without motor blockage by reaching the sensory nerve branches of the glenohumeral joint.The aim of this study was to compare the results between interscalene block and pericapsular nerve group block in patients undergoing shoulder surgery.

Official Title
-----------------
Comparison of Postoperative Analgesic Consumption and Pain in Shoulder Surgery Patients Undergoing Interscalene and Pericapsular Nerve Group (PENG) Blocks

Conditions
-----------------
Visual Analogue Score

Intervention / Treatment
-----------------
* Procedure: PENG Block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years and over American Society of Anesthesiologists (ASA) 1 and 2 shoulder surgery Exclusion Criteria: under 18 years old American Society of Anesthesiologists (ASA) 3 and above who are allergic to local anesthetics patients with infection at the injection site pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: interscalene block<br> | Procedure: PENG Block<br>* Pericapsular nerve group block in shoulder surgery.<br>|
| Active Comparator: PENG block<br> | Procedure: PENG Block<br>* Pericapsular nerve group block in shoulder surgery.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Analogue Scale | Visual Analogue Scale | 5 months |
Effect of Storage Condition on CD47 Expression Level in Platelet Concentrate

Study Overview
=================
Brief Summary
-----------------
Effect of storage condition on CD47 expression level in platelet concentrate

Detailed Description
-----------------
CD47 is a cell surface glycoprotein expressed on all cell types .It is an attractive target for therapy because it is involved in regulation of cell survival and cell death by acting as a ligand for signal-regulatory protein alpha expressed on macrophages

Official Title
-----------------
Effect of Storage Condition on CD47 Expression Level in Platelet Concentrate

Conditions
-----------------
Platelet Storage Pool Deficiency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: donors met AABB criteria Exclusion Criteria: donors not met AABB criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of CD47 expression level on platelets by exposure to different storage temperatures | To increase survival time of platelets | 3 years |
Progesterone on the Day of Ovulation Induction is Associated With Pregnancy Outcome

Study Overview
=================
Brief Summary
-----------------
Progesterone levels measured in blood/serum of patients on the day of ovulation induction following controlled ovarian stimulation for in vitro fertilization may be associated with pregnancy outcome. The hypothesis is that higher progesterone levels are associated with lower implantation rates due to changes in the endometrial receptivity.

Official Title
-----------------
Association Between Progesterone Levels on the Day of Ovulation Induction and IVF Outcome: Retrospective Study With 2500 Controlled Ovarian Stimulations Cycles

Conditions
-----------------
Female Infertility

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: IVF/ICSI following controlled ovarian stimulation progesterone measured on the day of ovulation induction informed consent Exclusion Criteria: missing consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Low level progesterone group (1)<br>Progesterone < 1.50 ng/mL on day of ovulation induction | |
| Medium level progesterone group (2)<br>Progesterone 1.51-1.99 ng/mL on the day of ovulation induction | |
| High level progesterone group (3)<br>Progesterone > 1.99 ng/mL on the day of ovulation induction | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ongoing pregnancy rate | Patients will be followed up from embryotransfer until second trimester of pregnancy | 13 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Delivery after 23.gestational weeks | Patients will be followed up from embryotransfer until delivery | 9 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IVF, progesterone, ovulation induction, pregnancy rates, Female Infertility Due to Nonimplantation
Trial to Evaluate the Efficacy of the HLPFC Coil Deep Transcranial Magnetic Stimulation System in Treating Attention Deficit and Hyperactivity Disorder (ADHD) in Adults

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate the efficacy of trans-cranial magnetic stimulation in treating attention deficit disorder in adults.

Conditions
-----------------
Attention Deficit Disorder Patients

Intervention / Treatment
-----------------
* Procedure: Transcranial Magnetic Stimulation. PFC


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-65 years ADD/ADHD Exclusion Criteria: any DSM-IV psychiatric disorder except ADD/ADHD use of psychoactive medications Epilepsy brain injury

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sham Comparator: control<br>control-sham | Procedure: Transcranial Magnetic Stimulation. PFC<br> <br> * Other names: Coil: HLPFC. Brainsway Ltd. 19 hartum St. Bynet Building, Har Hatzofim, Jerusalem, Israel.;|
| Active Comparator: Deep TMS PFC Lt<br>Deep TMS PFC left | Procedure: Transcranial Magnetic Stimulation. PFC<br> <br> * Other names: Coil: HLPFC. Brainsway Ltd. 19 hartum St. Bynet Building, Har Hatzofim, Jerusalem, Israel.;|
| Active Comparator: DEEP TMS PFC Rt<br>DEEP TMS PFC Rt | Procedure: Transcranial Magnetic Stimulation. PFC<br> <br> * Other names: Coil: HLPFC. Brainsway Ltd. 19 hartum St. Bynet Building, Har Hatzofim, Jerusalem, Israel.;|
| Active Comparator: Superficial TMS PFC Lt<br>Superficial TMS PFC Lt | Procedure: Transcranial Magnetic Stimulation. PFC<br> <br> * Other names: Coil: HLPFC. Brainsway Ltd. 19 hartum St. Bynet Building, Har Hatzofim, Jerusalem, Israel.;|
| Active Comparator: superficial TMS PFC Rt<br>superficial TMS PFC Rt | Procedure: Transcranial Magnetic Stimulation. PFC<br> <br> * Other names: Coil: HLPFC. Brainsway Ltd. 19 hartum St. Bynet Building, Har Hatzofim, Jerusalem, Israel.;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
age 18-65